Pradeep Avani R, Patnaik Kaushik, Nagpal Kanika, Karvekar Shruti, Ramamurthy Bhaskar L, Naik Savitha B, Suke Deepak, Singh Priyanka, Raju Arjun
Department of Periodontics, Government Dental College and Research Institute, Bangalore, Karnataka, India.
Oxford Dental College and Hospital, Bangalore, Karnataka, India.
J Investig Clin Dent. 2016 Aug;7(3):239-45. doi: 10.1111/jicd.12150. Epub 2015 Mar 18.
Metformin (MF), used for the treatment of type 2 diabetes mellitus, has shown to possess properties favoring osteoblastic proliferation. The present study was designed to investigate the effectiveness of MF 1% gel as an adjunct to scaling and root planing in the treatment of intrabony defects in patients with chronic periodontitis.
The study comprised 65 individuals divided into two groups: 1% MF with SRP and placebo gel with SRP. Clinical parameters were evaluated at baseline, 3 months, and 6 months; they included plaque index, modified sulcus bleeding index, probing depth (PD), and clinical attachment level (CAL). Intrabony defect depth (IBD) was evaluated at the end of 6 months using computer-aided software.
The mean PD reduction, CAL gain, and IBD depth reduction were found to be greater in the MF group than in the placebo group at all visits. The percentage of defect depth reduction was significantly greater in the MF group (26.8 ± 5.52%) than in the placebo sites (4.79 ± 2.30%, P < 0.001).
One percent MF was found to significantly improve clinical and radiographic parameters in intrabony defects in patients with chronic periodontitis.
二甲双胍（MF）用于治疗2型糖尿病，已显示出具有促进成骨细胞增殖的特性。本研究旨在调查1% MF凝胶作为慢性牙周炎患者骨内缺损治疗中龈下刮治和根面平整辅助治疗的有效性。
该研究包括65名个体，分为两组：1% MF联合龈下刮治和根面平整组以及安慰剂凝胶联合龈下刮治和根面平整组。在基线、3个月和6个月时评估临床参数；包括菌斑指数、改良龈沟出血指数、探诊深度（PD）和临床附着水平（CAL）。在6个月结束时使用计算机辅助软件评估骨内缺损深度（IBD）。
在所有访视中，发现MF组的平均PD降低、CAL增加和IBD深度降低均大于安慰剂组。MF组的缺损深度降低百分比（26.8±5.52%）显著大于安慰剂组（4.79±2.30%，P<0.001）。
发现1% MF可显著改善慢性牙周炎患者骨内缺损的临床和影像学参数。
